Marcadores clínicos e laboratoriais como preditores de eventos adversos maternos e neonatais em pacientes com diagnóstico de pré-eclâmpsia precoce com critérios de gravidade

• Ano de defesa: 2020
• Autor(a) principal: Luana Lopes de Toledo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Minas Gerais; Brasil; Programa de Pós-Graduação em Saúde da Mulher; UFMG
• Palavras-chave em Português: Pré-eclâmpsia; Complicações; Desfechos adversos; Predição; Pré-Eclâmpsia; Complicações na Gravidez; Previsões; Indicadores de Morbimortalidade; Prognóstico; Saúde da Mulher; Dissertação Acadêmica
• Link de acesso: http://hdl.handle.net/1843/54910

Introduction: Pre-eclampsia (PE) is still one of the most important causes of maternal and perinatal morbidity and mortality in the word, especially when its early manifestations (before 34 weeks) are considered. Therefore, it is essential to focus on developing objective methods to predict the risk of adverse outcomes in this patients. This enables an individualized clinical approach, potentially assuring better prognosis. Objectives: Evaluate a clinical and some laboratorial markers as potential predictors of adverse outcomes in women with early and severe PE. Patients and Methods: A retrospective analysis of charts was conducted, selecting 97 patients with early and severe PE who gave birth under 34 weeks, between 01/01/2014 and 31/12/2017 in Risoleta Tolentino Neves Hospital, in Belo Horizonte. Using the data collected, Reciever Operating Characteristic (ROC) Curves were developed, relating Medium Arterial Pressure, platelet count, serum creatinin levels, and Aspartate Aminotransferase (AST) levels with maternal adverse outcomes and neonatal adverse outcomes. Results: Amongst evaluated variables, only platelet count presented an Area Under The Curve (AUC) significant enough to predict neonatal complications. For predicting maternal adverse outcomes, AST and platelet count had a significant AUC. However, the other markers did not demonstrate a good performance as predictors of adverse maternal or neonatal outcomes. Conclusion: The present study shows that AST and platelet count can be used as potential markers of the risk of complications in patients with early and severe PE.